Vivek Subbiah, MD
Specialities
- Endocrine cancer
- Precision oncology
- Sarcoma cancer
- Targeted therapy and immunotherapy
- Clinical trials and research advancements
Education
Medical Degree: Sri Ramachandra Medical College
Residency: Case Western Reserve University
Fellowship: University of Texas MD Anderson Cancer Center
Location
335 24th Avenue North, Suite 200
Nashville, Tennessee 37203
Phone: 615-329-7640
Fax: 615-234-7723
Language
English
Biography
Dr. Vivek Subbiah is a medical oncologist at SCRI Oncology Partners and serves as the chief of early-phase drug development at SCRI. He has served as the principal investigator in over 100 phase I/II trials and as a co-investigator in over 200 clinical trials. Dr. Subbiah has authored over 350 peer-reviewed publications in several high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, The Lancet Oncology, Nature Reviews Clinical Oncology, The Lancet Diabetes and Endocrinology, and Clinical Cancer Research.
Philosophy
Dr. Vivek Subbiah is dedicated to providing access to the latest advancements in cancer treatment and clinical trials. He strives to make sure each patient’s unique needs are taken into consideration. He works with a team of multidisciplinary experts to deliver individualized treatment plans to each patient.
Relevant Research
Trends in Cancer
Pearls and pitfalls of ChatGPT in medical oncology
JCO Precision Oncology
Targeting All BRAF Alterations: The (Re)-Search Continues
Cell Reports Medicine
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers